China’s army gives limited approval to potential Covid-19 vaccine

China’s army gives limited approval to potential Covid-19 vaccine

Currently, more than 200 vaccine candidates are at different stages of development and 15 have reached human clinical trials, Swaminathan said.

But CanSino said that it can not guarantee that the vaccine, which has undergone both phase one and two clinical trials in China, will ultimately be commercialised.

China's military has been given the green light to use a Covid-19 vaccine candidate, after clinical trials yielded positive results. The shot also won approval for human testing in Canada.

Reports suggest that China, which is among front-runners in the race to find a COVID-19 jab, is developing coronavirus vaccines in five categories - inactivated vaccines, recombinant protein vaccines, live attenuated influenza vaccines, adenovirus vaccines and nucleic acid-based vaccines.

CanSino Biologics, a Chinese laboratory based in Shanghai, has been granted permission for its coronavirus vaccine to be used by the country's military after clinical trials proved hopeful.

CanSino said Monday that China's Central Military Commission approved the use of the vaccine on June 25, for one year.

Japanese Startup Makes 'Connected' Face Mask for Coronavirus Crisis
The company said it has plans to sell products in China also and later in The US and Europe. It's now aiming to generate revenue through its subscribe based services through its apps.

A potential coronavirus vaccine, Ad5-nCoV has been granted limited approval in China.

CanSino revealed it had received a certificate from China's National Medical Products Administration to launch clinical trials.

"The Ad5-nCoV is now limited to military use only and its use can not be expanded to a broader vaccination range without the approval of the Logistics Support Department", CanSino said, referring to the Central Military Commission department where the military use of the vaccine was approved.

More than half of 17 candidate vaccines identified by the World Health Organization (WHO) that are in clinical evaluation involve Chinese companies or institutes.

As of Monday, the country had tallied 1.35 million cases of COVID-19 and almost 58,000 deaths, according to case tracker Worldometers.

Related Articles